483
Mylan Laboratories LimitedFDA 483 - Mylan Laboratories Limited - September 23, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
Mylan Laboratories Limited's Hosur Sterile Facility received a Form 483 with six observations related to significant deficiencies in their manufacturing processes for sterile drug products. The inspection revealed issues with equipment performance, environmental monitoring, aseptic process validation, and quality control oversight. These findings indicate a lack of adherence to cGMPs, potentially compromising the sterility and quality of their drug products.
Open in Dashboard
ID · 457f945a-2cf0-47ff-a725-b22f8dfe412b